Loading...

REGENXBIO

DB:RB0
Snowflake Description

Flawless balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
RB0
DB
$2B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The last earnings update was 50 days ago. More info.


Add to Portfolio Compare Print
RB0 Share Price and Events
7 Day Returns
-2.6%
DB:RB0
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
47.7%
DB:RB0
-9.2%
DE Biotechs
-6.7%
DE Market
RB0 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
REGENXBIO (RB0) -2.6% -6.3% 21.1% 47.7% 384.7% -
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • RB0 outperformed the Biotechs industry which returned -9.2% over the past year.
  • RB0 outperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
RB0
Industry
5yr Volatility vs Market
Related Companies

Value

 Is REGENXBIO undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of REGENXBIO to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for REGENXBIO.

DB:RB0 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:RB0
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.46
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.456 (1 + (1- 21%) (0.29%))
1.308
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.31
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.308 * 5.96%)
8.02%

Discounted Cash Flow Calculation for DB:RB0 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for REGENXBIO is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:RB0 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.02%)
2019 -80.00 Analyst x1 -74.06
2020 -41.00 Analyst x1 -35.14
2021 89.00 Analyst x1 70.61
2022 156.00 Analyst x1 114.57
2023 203.00 Analyst x1 138.02
2024 240.37 Est @ 18.41% 151.29
2025 271.51 Est @ 12.95% 158.19
2026 296.32 Est @ 9.14% 159.83
2027 315.47 Est @ 6.46% 157.52
2028 329.96 Est @ 4.59% 152.52
Present value of next 10 years cash flows $993.34
DB:RB0 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $329.96 × (1 + 0.23%) ÷ (8.02% – 0.23%)
$4,242.99
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $4,242.99 ÷ (1 + 8.02%)10
$1,961.26
DB:RB0 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $993.34 + $1,961.26
$2,954.60
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $2,954.60 / 36.61
$80.7
DB:RB0 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:RB0 represents 0.87868x of NasdaqGS:RGNX
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.87868x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 80.70 x 0.87868
€70.91
Value per share (EUR) From above. €70.91
Current discount Discount to share price of €48.02
= -1 x (€48.02 - €70.91) / €70.91
32.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price REGENXBIO is available for.
Intrinsic value
32%
Share price is €48.02 vs Future cash flow value of €70.91
Current Discount Checks
For REGENXBIO to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • REGENXBIO's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • REGENXBIO's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for REGENXBIO's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are REGENXBIO's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:RB0 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $2.99
NasdaqGS:RGNX Share Price ** NasdaqGS (2019-04-18) in USD $54.65
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of REGENXBIO.

DB:RB0 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:RGNX Share Price ÷ EPS (both in USD)

= 54.65 ÷ 2.99

18.28x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • REGENXBIO is good value based on earnings compared to the Europe Biotechs industry average.
  • REGENXBIO is good value based on earnings compared to the Germany market.
Price based on expected Growth
Does REGENXBIO's expected growth come at a high price?
Raw Data
DB:RB0 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 18.28x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
-73.2%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

DB:RB0 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 18.28x ÷ -73.2%

-0.25x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • REGENXBIO earnings are not expected to grow next year, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on REGENXBIO's assets?
Raw Data
DB:RB0 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $14.09
NasdaqGS:RGNX Share Price * NasdaqGS (2019-04-18) in USD $54.65
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:RB0 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:RGNX Share Price ÷ Book Value per Share (both in USD)

= 54.65 ÷ 14.09

3.88x

* Primary Listing of REGENXBIO.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • REGENXBIO is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess REGENXBIO's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. REGENXBIO has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is REGENXBIO expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-73.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is REGENXBIO expected to grow at an attractive rate?
  • REGENXBIO's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 0.2%.
Growth vs Market Checks
  • REGENXBIO's earnings are expected to decrease over the next 1-3 years, this is below the Germany market average.
  • REGENXBIO's revenues are expected to decrease over the next 1-3 years, this is below the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:RB0 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:RB0 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts -73.2%
DB:RB0 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts -29.8%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:RB0 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:RB0 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 225
2022-12-31 177
2021-12-31 147 107 -55 1
2020-12-31 111 -26 -87 4
2019-12-31 26 -67 -123 4
DB:RB0 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 219 105 100
2018-09-30 180 95 80
2018-06-30 176 97 78
2018-03-31 142 18 53
2017-12-31 10 -58 -73
2017-09-30 10 -65 -77
2017-06-30 9 -59 -74
2017-03-31 5 -58 -74
2016-12-31 5 -49 -63
2016-09-30 7 -33 -49
2016-06-30 8 -29 -38
2016-03-31 7 -29 -32

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • REGENXBIO's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • REGENXBIO's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:RB0 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from REGENXBIO Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:RB0 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 -1.13 -1.13 -1.13 1.00
2020-12-31 -2.10 -0.61 -3.54 4.00
2019-12-31 -3.17 -2.21 -3.82 4.00
DB:RB0 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 2.99
2018-09-30 2.47
2018-06-30 2.48
2018-03-31 1.71
2017-12-31 -2.45
2017-09-30 -2.68
2017-06-30 -2.69
2017-03-31 -2.80
2016-12-31 -2.38
2016-09-30 -1.84
2016-06-30 -1.80
2016-03-31 -2.12

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if REGENXBIO will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess REGENXBIO's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
REGENXBIO has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has REGENXBIO performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare REGENXBIO's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • REGENXBIO has delivered over 20% year on year earnings growth in the past 5 years.
  • REGENXBIO has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • REGENXBIO has become profitable in the last year making it difficult to compare the Europe Biotechs industry average.
Earnings and Revenue History
REGENXBIO's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from REGENXBIO Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:RB0 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 218.51 99.94 36.85
2018-09-30 179.77 79.63 30.51
2018-06-30 175.80 78.13 30.95
2018-03-31 142.33 53.06 28.99
2017-12-31 10.39 -73.17 27.23
2017-09-30 10.05 -76.78 28.16
2017-06-30 8.84 -74.23 24.92
2017-03-31 4.65 -74.19 24.73
2016-12-31 4.59 -62.97 23.59
2016-09-30 7.34 -48.54 22.09
2016-06-30 8.35 -37.72 18.45
2016-03-31 7.34 -32.07 15.68
2015-12-31 7.59 -23.80 11.91
2015-09-30 4.29 -21.18 8.79
2015-06-30 3.64 -15.76 7.30
2015-03-31 3.83 -7.53 4.93
2014-12-31 6.12 -4.82 3.85
2013-12-31 6.09 -5.81 5.47

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • REGENXBIO has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • REGENXBIO used its assets more efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • REGENXBIO has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess REGENXBIO's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
REGENXBIO has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is REGENXBIO's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up REGENXBIO's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • REGENXBIO is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • REGENXBIO's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of REGENXBIO's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 57.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from REGENXBIO Company Filings, last reported 3 months ago.

DB:RB0 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 508.85 5.85 319.76
2018-09-30 494.06 0.00 372.59
2018-06-30 317.22 0.00 286.49
2018-03-31 299.34 0.00 229.87
2017-12-31 183.03 0.00 160.78
2017-09-30 194.65 0.00 166.66
2017-06-30 211.70 0.00 162.08
2017-03-31 212.90 0.00 145.81
2016-12-31 161.74 0.00 89.55
2016-09-30 180.23 0.00 91.77
2016-06-30 196.18 0.00 94.21
2016-03-31 208.60 0.00 101.06
2015-12-31 216.81 0.00 114.14
2015-09-30 221.81 0.00 213.35
2015-06-30 82.63 0.00 85.22
2015-03-31 20.20 0.00 25.37
2014-12-31 -5.70 3.83 1.12
2013-12-31 -2.14 0.66 1.12
  • REGENXBIO's level of debt (1.2%) compared to net worth is satisfactory (less than 40%).
  • REGENXBIO had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
  • Debt is well covered by operating cash flow (1787.6%, greater than 20% of total debt).
  • REGENXBIO earns more interest than it pays, coverage of interest payments is not a concern.
X
Financial health checks
We assess REGENXBIO's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. REGENXBIO has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is REGENXBIO's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from REGENXBIO dividends. Estimated to be 0% next year.
If you bought €2,000 of REGENXBIO shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate REGENXBIO's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate REGENXBIO's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:RB0 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:RB0 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as REGENXBIO has not reported any payouts.
  • Unable to verify if REGENXBIO's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of REGENXBIO's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as REGENXBIO has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of REGENXBIO's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess REGENXBIO's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can REGENXBIO afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. REGENXBIO has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of REGENXBIO's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ken Mills
COMPENSATION $2,543,136
AGE 43
TENURE AS CEO 10.1 years
CEO Bio

Mr. Kenneth T. Mills, also known as Ken, has been the Chief Executive Officer and President at REGENXBIO Inc. since March 2009. Mr. Mills served as the Chief Financial Officer and Vice President of Business Development at Meso Scale Diagnostics, where he worked as part of the founding management establish its operations and ongoing business strategy. As part of his responsibilities, Mr. Mills supervised all company affairs, including direct management of corporate and business development, strategic planning, as well as finance and accounting activities. Mr. Mills has been a Director of REGENXBIO Inc. since March 2009. He served as a Director of Business Development for IGEN International, a medical diagnostics company. Mr. Mills received an S.B. in chemistry from the Massachusetts Institute of Technology.

CEO Compensation
  • Ken's compensation has been consistent with company performance over the past year.
  • Ken's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the REGENXBIO management team in years:

2.7
Average Tenure
49.5
Average Age
  • The tenure for the REGENXBIO management team is about average.
Management Team

Ken Mills

TITLE
CEO, President & Director
COMPENSATION
$3M
AGE
43
TENURE
10.1 yrs

Vit Vasista

TITLE
Chief Financial Officer
COMPENSATION
$1M
AGE
50
TENURE
9.7 yrs

Olivier Danos

TITLE
Chief Scientific Officer
COMPENSATION
$2M
AGE
60
TENURE
2.1 yrs

Curran Simpson

TITLE
Senior VP of Product Development & Chief Technology Officer
COMPENSATION
$1M
AGE
56
TENURE
3.7 yrs

Patrick Christmas

TITLE
Senior VP & General Counsel
AGE
47
TENURE
2.7 yrs

Andrew Yost

TITLE
Vice President of Corporate Development
TENURE
2.1 yrs

Shiva Fritsch

TITLE
Senior Vice President of Human Resources
TENURE
1.5 yrs

Laura Coruzzi

TITLE
Senior Vice President of Intellectual Property
TENURE
2.9 yrs

Ram Palanki

TITLE
Senior VP of Commercial Strategy & Operations
TENURE
0.7 yrs

Steve Pakola

TITLE
Senior VP & Chief Medical Officer
AGE
49
Board of Directors Tenure

Average tenure and age of the REGENXBIO board of directors in years:

4
Average Tenure
64.5
Average Age
  • The tenure for the REGENXBIO board of directors is about average.
Board of Directors

Don Hayden

TITLE
Chairman of the Board
COMPENSATION
$228K
AGE
62
TENURE
6.2 yrs

Ken Mills

TITLE
CEO, President & Director
COMPENSATION
$3M
AGE
43
TENURE
10.1 yrs

Luke Beshar

TITLE
Independent Director
COMPENSATION
$208K
AGE
59
TENURE
4 yrs

Jerry Karabelas

TITLE
Independent Director
COMPENSATION
$196K
AGE
66
TENURE
3.9 yrs

Allan Fox

TITLE
Director
COMPENSATION
$188K
AGE
70
TENURE
10.2 yrs

Judith Swain

TITLE
Member of Scientific Advisor
AGE
69

Inder Verma

TITLE
Member of Scientific Advisor
AGE
70

Dave Stump

TITLE
Independent Director
COMPENSATION
$200K
AGE
68
TENURE
3.5 yrs

Dan Abdun-Nabi

TITLE
Independent Director
COMPENSATION
$196K
AGE
63
TENURE
2.7 yrs

Daniel Tassé

TITLE
Independent Director
COMPENSATION
$193K
AGE
58
TENURE
2.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess REGENXBIO's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. REGENXBIO has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. The company’s lead product candidate is RGX-314, which is in Phase I/IIa clinical trials for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trials to treat mucopolysaccharidosis type II; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

Details
Name: REGENXBIO Inc.
RB0
Exchange: DB
Founded: 2008
$1,779,911,440
36,611,157
Website: http://www.regenxbio.com
Address: REGENXBIO Inc.
9600 Blackwell Road,
Suite 210,
Rockville,
Maryland, 20850,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS RGNX Common Shares Nasdaq Global Select US USD 17. Sep 2015
DB RB0 Common Shares Deutsche Boerse AG DE EUR 17. Sep 2015
Number of employees
Current staff
Staff numbers
192
REGENXBIO employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 22:20
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/12
Last earnings filing: 2019/02/27
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.